NASDAQ · TELA
Healthcare · Medical - Devices
$1.07
Down-$0.07 (-6.54%)
Updated Oct 8, 2026, 1:56 PM
SID Score
5.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · TELA
1M range · 0 trading sessions · Daily adjusted prices
TELA does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning TELA.
Company
Market Activity
Research & News
TELA research
Company profile and research snapshot.
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 25, 2026 | Craig-Hallum | Buy | — |
| Mar 27, 2026 | Citizens | Market Outperform | — |
| Mar 25, 2026 | Lake Street | Buy | — |
| Mar 25, 2026 | Piper Sandler | Neutral | — |
| Mar 25, 2026 | Canaccord Genuity | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 25, 2026
Craig-Hallum analyst Chase Knickerbocker initiates coverage on TELA Bio (NASDAQ:TELA) with a Buy rating and announces Price Target of $2.
Yahoo · Aug 31, 2026
Company to reduce annual operating expenses by $17.0 million or 18% as part of broader efficiency programMALVERN, Pa., Aug. 31, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that Roberto Cuca, Chief Operating Officer and Chief Financial Officer, will step down from the role effective today. “On behalf of the Board and management team, I woul
Benzinga · Aug 31, 2026
TELA Bio, Inc. ("TELA Bio" or the "Company"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that Roberto Cuca, Chief
Benzinga · Aug 31, 2026
TELA Bio, Inc. ("TELA Bio" or the "Company"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that Roberto Cuca, Chief
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TELA.
